Wester Tomas, Granström Anna Löf
Section of Pediatric Surgery, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden,
Pediatr Surg Int. 2015 Mar;31(3):255-9. doi: 10.1007/s00383-015-3665-4. Epub 2015 Jan 24.
Obstructive symptoms are common after pull-through for Hirschsprung disease. Botulinum toxin injection treatment may improve the bowel function if internal sphincter achalasia is the cause of obstructive symptoms. The aim of this study was to review the outcome in patients treated with intrasphincteric botulinum toxin injections after pull-through for Hirschsprung disease.
The operative records were used to identify children with Hirschsprung disease who were treated with botulinum toxin injections at Karolinska University Hospital, Stockholm, Sweden, from September 2007 to November 2014. Data on age, sex, associated syndromes, length of aganglionic segment, age at pull-through, type of pull-through, age at first botulinum toxin injection, indication for botulinum toxin injection, and effect of first botulinum toxin injection were retrieved from the case records. Bowel function at last follow-up visit or telephone contact was recorded.
Nineteen patients were identified. All had biopsy-verified Hirschsprung disease. Eighteen (15 males and 3 females) children had undergone intrasphincteric botulinum toxin injection treatment for obstructive symptoms after pull-through, which was done at 127 (18-538) days of age. Four children had total colonic aganglionosis. The first botulinum toxin injection was given at 2.4 (0.53-6.9) years of age. Thirteen children (72 %) had a good response to the first injection treatment. The children underwent 3 (1-13) injection treatments. At follow-up four patients had improved and did not need treatment for obstruction, four were scheduled for further botulinum toxin injections, eight had persistent obstructive symptoms treated with laxatives or enemas, and two children had an ileostomy.
Botulinum toxin injection treatment improves the obstructive symptoms in children after pull-through for Hirschsprung disease. The effect is reversible and a majority of patients need repeat injections. When injection treatment is not repeated, a large proportion of children need laxatives or enemas due to recurrent symptoms.
先天性巨结肠症拖出术后梗阻症状很常见。如果内括约肌失弛缓症是梗阻症状的病因,肉毒杆菌毒素注射治疗可能改善肠道功能。本研究的目的是回顾先天性巨结肠症拖出术后接受括约肌内注射肉毒杆菌毒素治疗患者的结局。
利用手术记录确定2007年9月至2014年11月在瑞典斯德哥尔摩卡罗林斯卡大学医院接受肉毒杆菌毒素注射治疗的先天性巨结肠症患儿。从病例记录中检索年龄、性别、相关综合征、无神经节段长度、拖出术时年龄、拖出术类型、首次肉毒杆菌毒素注射年龄、肉毒杆菌毒素注射指征以及首次肉毒杆菌毒素注射效果等数据。记录最后一次随访就诊或电话联系时的肠道功能。
确定了19例患者。所有患者均经活检证实为先天性巨结肠症。18例(15例男性和3例女性)儿童在拖出术后因梗阻症状接受了括约肌内肉毒杆菌毒素注射治疗,注射时间为127(18 - 538)日龄。4例儿童患有全结肠无神经节症。首次肉毒杆菌毒素注射年龄为2.4(0.53 - 6.9)岁。13例儿童(72%)对首次注射治疗反应良好。这些儿童接受了3(1 - 13)次注射治疗。随访时,4例患者病情改善,无需进行梗阻治疗;4例计划进一步注射肉毒杆菌毒素;8例有持续梗阻症状,接受泻药或灌肠治疗;2例儿童行回肠造口术。
肉毒杆菌毒素注射治疗可改善先天性巨结肠症拖出术后儿童的梗阻症状。这种效果是可逆的,大多数患者需要重复注射。当不重复注射治疗时,很大一部分儿童因症状复发需要使用泻药或灌肠。